首页
登录
职称英语
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administ
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administ
游客
2023-12-27
23
管理
问题
Celebrate. Celebrate. Physicians are delighted with a Food and Drug Administration(FDA)advisory panel’s recommendation earlier this year that Vioxx and its cousins Bextra and Celebrex(all medicines known as Cox-2 inhibitors)should remain on the market, despite evidence they increase heart disease risk in some people. The panelists reached their decision after weighing all the data and concluding the benefits of these pain-relieving drugs outweighed the risks.
Specifically, these scientists acknowledged that, for some patients, these prescription drugs were uniquely effective in reducing pain from arthritis and other causes. For others—concerned about ulcers associated with aspirin and other OTC analgesics—the Cox-2 inhibitors offered the advantage of minimizing potentially serious effects of stomach irritation.
Now is an appropriate time for everyone to take a fresh look at the benefit-risk equation for Vioxx and the other Cox-2 inhibitors.
The risks— increased risk of heart disease in some who use the drugs—have been well publicized. Much less publicity has been given to a spectrum of real and potential benefits that go way beyond reduced risk of stomach irritation. These little-discussed benefits would have been lost, perhaps permanently-had Vioxx, Bextra and Celebrex been driven from shelves in pursuit of perfect safety, an unattainable goal.
For example, there is substantial evidence Cox-2 inhibitors can reduce development of colon polyps, which may become colon canceL Indeed. Celebrex is FDA-approved for those genetically prone to colon cancer. Ironically, the 2004 study that revealed the elevated heart attack risk of Vioxx was primarily designed to further establish the drug’s effectiveness in protecting against colon cancer. And while the results of that interrupted trial have not yet been published, there is good reason to believe they will confirm the protective effects against colon cancer established in research over the last 10 years.
At the time of its withdrawal from the market last fall, studies of Vioxx as well as the other Cox-2 drugs suggest that they had other anti-cancer properties as well, possibly reducing the risk of malignancies of a number of sites, including the lung and esophagus.
Had these drugs been dismissed, their untapped promise for prevention would have evaporated well before it was evaluated and applied to save lives. Fortunately, cooler and wiser heads prevailed. [br] The phase "on the market" underlined in Paragraph 1 is closest in meaning to______.
选项
A、for sale
B、sell
C、to be listed
D、go public
答案
A
解析
根据文中第一段的内容“Vioxx and its cousins Bextra and Celebrex(all medicinesknown as Cox-2 inhibitors)should remain on the market”可知,它们可在市场上销售。选项中的A项为“出售”符合文意。B项“卖”,C项“上市”,D项“公开”,这三项均不符合题意。
转载请注明原文地址:https://tihaiku.com/zcyy/3308684.html
相关试题推荐
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
Washington:TheBushadministrationhas【L1】______forthefirsttimethatit
随机试题
ObtainingLinguisticDataA)Manyproceduresareavailabl
《中华人民共和国反不正当竞争法》规定:经营者不得以排挤竞争对手为目的,以低于成本
装于同一相变比相同且容量相同的电流互感器,在二次绕组串联使用时()。A.容量和
以下因素哪项与结核性脑膜炎的预后无关A.治疗的早晚 B.结核性脑膜炎的病期
简述员工在企业各个部门之间或者在不同类型岗位之间实施必要的工作轮换具有的益处。
近日,某市一商业街出现了一个街头卖艺表演的临时摊点。一名外地中年男子在每天下午人
下列各项中,属于企业管理会计主要目标的是()。A.提供现金流量信息 B.提
对于立井井筒基岩的短段掘砌作业,井壁现浇混凝土衬砌时通常采用()模板。A、拆卸式
喹诺酮类A.抑制细菌细胞壁合成 B.抑制细菌二氢叶酸还原酶 C.抑制细菌DN
关于施工总承包模式的说法,正确的是()。A.工程质量的好坏取决于业主的管理水平
最新回复
(
0
)